A Phase 2 interventional study of rAvPAL-PEG in Phenylketonuria, sponsored by BioMarin Pharmaceutical. Completed at 9 sites in United States. Open to participants aged 16 Years to 70 Years. Per ClinicalTrials.gov, last updated 2019-02-26.
Sponsored by BioMarin Pharmaceutical · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing pegvaliase in Phenylketonurias — 1 open to participants now, 2 under way, 1 of them phase 3. pegvaliase · Phenylketonurias.
Among the 10 studies testing pegvaliase in Phenylketonurias, this one is the 9th largest by enrollment, is the only one that started in 2011, is one of 4 in phase 2, and was the 4th registered.
191 studies on the registry are indexed under Phenylketonurias; 40 are open to participants now.
Browse Phenylketonurias studies →1 of the 10 studies testing pegvaliase in Phenylketonurias is open now, in 1 country. Recruiting first, the newest first:
BioMarin Pharmaceutical · Sites in United States
Ages 18–65
By country, each count listing its studies:
pegvaliase: first FDA approval 2018 (PALYNZIQ), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 31 Phenylketonurias studies recruiting now, 14 (45%) set no upper age limit and 17 (55%) stop at 75 or younger; 15 take children under 18; 8 take healthy volunteers.
This study: 16 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 1 started in 2011.
This study's enrollment of 16 is below the median of 27 across 122 interventional studies indexed under Phenylketonurias.
Median enrollment 39 across the 10 interventional studies. Of the 8 that completed or were terminated, 7 (88%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 10 have an industry lead sponsor. The 1 most frequent:
BioMarin Pharmaceutical is the lead sponsor of 112 studies on the registry; 13 are open to participants now.
Of its 19 completed or terminated interventional studies of FDA-regulated products, 12 (63%) have results posted.
35 studies in Phenylketonurias by BioMarin Pharmaceutical: 3 open now, 5 under way, 1 of them phase 3. Of 29 finished, 17 (59%) have results posted.
Among the 35 studies in Phenylketonurias by BioMarin Pharmaceutical, this one is the 22nd largest by enrollment of the 26 interventional ones that give a count, is one of 2 that started in 2011, is one of 9 in phase 2, and was the 18th registered.
BioMarin Pharmaceutical’s Phenylketonurias studies by the year they started, since 2004.
1 of the studies testing pegvaliase in Phenylketonurias that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07477691BioMarin PharmaceuticalImmune Modulation During Palynziq® Treatment in Adults (IMPALA) | 2027-09-30 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies testing pegvaliase in Phenylketonurias, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among BioMarin Pharmaceutical’s 35 in Phenylketonurias:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the effect of daily administration of rAvPAL-PEG on the reduction of blood Phe concentrations in subjects with PKU.
This 16-week multi-center, open-label, Phase 2 study is designed to evaluate the safety, tolerability,and efficacy of daily SC injections of rAvPAL-PEG in subjects with PKU. Subjects who are naïve to prior treatment with rAvPAL-PEG and who have met the other study eligibility criteria will be enrolled at approximately 8 sites in the US and Canada. Up to 6 daily dose levels of rAvPAL-PEG are planned and may be assessed during this study (0.06 mg/kg/day, 0.1 mg/kg/day, 0.2 mg/kg/day;0.4 mg/kg/day, 0.6 mg/kg/day, or 0.8 mg/kg/day). Enrollment will begin with the 0.4 mg/kg/day dose level and additional higher or lower doses may be added. The additional dose levels chosen for assessment will be based on the safety (systemic reaction or clinically significant abnormal laboratory test results assessed as related to study drug) and efficacy (blood Phe reduction to less than or equal to 60 μmol/L) information of at least 3 subjects with at least 2 weeks of daily dosing with rAvPAL-PEG. Initiation of dosing at higher or lower dose levels will be per the determination of the Sponsor's Medical Officer in consultation with the Investigator.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
rAvPAL-PEG in varying doses
Drug: rAvPAL-PEG
0.06 mg/kg/day, 0.1 mg/kg/day, 0.2 mg/kg/day, 0.4 mg/kg/day, 0.6 mg/kg/day, 0.8 mg/kg/day
Also known as: Recombinant Anabaena variabilis phenylalanine ammonia lyase
Blood Phenylalanine Concentration
Plasma Phe
Time frame: Baseline, Week 16
Study Drug Related Adverse Events
Safety will be evaluated on the incidence of AEs and clinically significant changes in vital signs as well as clinical labs and ECG. Please refer to AE section below for comprehensive listing of all adverse events recorded during study.
Time frame: Weekly
Percentage of Participants With PAL IgG Antibody Percentage of Participants With Positive PAL IgG
Antibody against phenylalanine ammonia lyase (PAL)
Time frame: Baseline, Week 16
Plasma Concentrations of rAvPAL-PEG (BMN 165)
Measurements taken pre-dose
Time frame: Baseline, Week 8, Week 13
Percentage of Participants With PEG-IgG Antibody Positivity
Antibodies against polyethylene glycol (PEG) of the IgG isotype
Time frame: Baseline, Week 16
Percentage of Participants With PAL-IgM Antibody Positivity
Antibodies against phenylalanine ammonia lyase (PAL) of the IgM isotype
Time frame: Baseline, Week 16
Percentage of Participants With PEG-IgM Antibody Positivity
Antibodies against polyethylene glycol (PEG) of the IgM isotype
Time frame: Baseline, Week 16
Percentage of Participants With Neutralizing Antibody Positivity
Antibody positivity over time
Time frame: Baseline, Week 16
Percentage of Participants With PAL-IgE Antibody Positivity
Antibodies against phenylalanine ammonia lyase (PAL) of the IgE isotype
Time frame: Baseline, Week 16
Percentage of Participants With PAL-PEG-IgE Antibody Positivity
Antibodies against phenylalanine ammonia lyase (PAL)-polyethylene glycol (PEG) of the IgE isotype
Time frame: Baseline, Week 16
| Milestone | rAvPAL-PEG |
|---|---|
| Started | 16 |
| Completed | 15 |
| Not completed | 1 |
| Withdrew: Withdrawal by subject | 1 |
Plasma Phe
| umol/L | rAvPAL-PEG |
|---|---|
| Baseline | 1482.1 ± 363.46 |
| Week 16 | 1566.0 ± 586.11 |
Safety will be evaluated on the incidence of AEs and clinically significant changes in vital signs as well as clinical labs and ECG. Please refer to AE section below for comprehensive listing of all adverse events recorded during study.
| Participants | Total |
|---|---|
| Study Drug Related Adverse Events | 16 |
Antibody against phenylalanine ammonia lyase (PAL)
| Percentage | Total |
|---|---|
| Baseline | 12.5 |
| Week 16 | 100.0 |
Measurements taken pre-dose
| ng/mL | rAvPAL-PEG |
|---|---|
| Baseline-Day 1, 1 Hour Predose | 0.000 ± 0.0000 |
| Week 8-Day 52, 1 Hour Predose | 2425.608 ± 8532.2431 |
| Week 13-Day 89, Predose | 1116.364 ± 2013.9676 |
Antibodies against polyethylene glycol (PEG) of the IgG isotype
| Percentage | Total |
|---|---|
| Baseline | 25.0 |
| Week 16 | 75.0 |
Antibodies against phenylalanine ammonia lyase (PAL) of the IgM isotype
| Percentage | Total |
|---|---|
| Baseline | 12.5 |
| Week 16 | 75.0 |
Antibodies against polyethylene glycol (PEG) of the IgM isotype
| Percentage | Total |
|---|---|
| Baseline | 31.3 |
| Week 16 | 50.0 |
Antibody positivity over time
| Percentage | Total |
|---|---|
| Baseline | 0.0 |
| Week 16 | 0.0 |
Antibodies against phenylalanine ammonia lyase (PAL) of the IgE isotype
| Percentage | Total |
|---|---|
| Baseline | 0.0 |
| Week 16 | 0.0 |
Antibodies against phenylalanine ammonia lyase (PAL)-polyethylene glycol (PEG) of the IgE isotype
| Percentage | Total |
|---|---|
| Baseline | 0.0 |
| Week 16 | 0.0 |
Collected over Week 0- Week 16. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| rAvPAL-PEG | 0/16 (0%) | 1/16 (6.3%) | 16/16 (100%) |
| Event | rAvPAL-PEG |
|---|---|
| AngioedemaSkin and subcutaneous tissue disorders | 1/16 |
| Event | rAvPAL-PEG |
|---|---|
| ArthralgiaMusculoskeletal and connective tissue disorders | 12/16 |
| HeadacheNervous system disorders | 10/16 |
| DizzinessNervous system disorders | 9/16 |
| Injection site erythemaGeneral disorders | 8/16 |
| Injection site reactionGeneral disorders | 8/16 |
| Injection site painGeneral disorders | 7/16 |
| Injection site bruisingGeneral disorders | 6/16 |
| Rash generalisedSkin and subcutaneous tissue disorders | 6/16 |
| DiarrhoeaGastrointestinal disorders | 5/16 |
| PyrexiaGeneral disorders | 5/16 |
| Age, Continuous(years) | rAvPAL-PEG |
|---|---|
| Mean | 32.2 ± 8.27 |
| Age, Customized(Participants) | rAvPAL-PEG |
|---|---|
| < 18 years of age | 0 |
| > or = 18 years of age | 16 |
| Sex: Female, Male(Participants) | rAvPAL-PEG |
|---|---|
| Female | 13 |
| Male | 3 |
| Ethnicity (NIH/OMB)(Participants) | rAvPAL-PEG |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 16 |
| Unknown or Not Reported | 0 |
| Race/Ethnicity, Customized(Participants) | rAvPAL-PEG |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 16 |
| Other | 0 |
Plan to share: No
The record gives a start of Mar 2011, a primary completion of Apr 2015 and a completion of Apr 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2019, 3 years 10 months after primary completion. A results delay was requested in Aug 2017.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pegvaliase